Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Cardiology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States.Circulation Heart failure. 2019; 12: e005407
- Transthyretin amyloid cardiomyopathy: JACC STATE-OF-THE-ART REview.J Am Coll Cardiol. 2019; 73: 2872-2891
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Eur Heart J. 2015; 36: 2585-2594
- Localization of the human prealbumin gene to chromosome 18.Biochem Biophys Res Commun. 1985; 129: 753-758
- Cardiac Amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association.Circulation. 2020; 142: e7-e22
- Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey).J Am Coll Cardiol. 2016; 68: 161-172
- Transthyretin V122I (pV142I)∗ cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.Genet Med. 2017; 19: 733-742
- The amyloidogenic V122I transthyretin variant in elderly black Americans.N Engl J Med. 2015; 372: 21-29
- Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.Am J Hematol. 2022; 97: 818-829
- Natural history and outcome in systemic AA amyloidosis.N Engl J Med. 2007; 356: 2361-2371
- The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.QJM. 1998; 91: 141-157
- Transthyretin (TTR) cardiac amyloidosis.Circulation. 2012; 126: 1286-1300
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-Diagnostic criteria and appropriate utilization.J Nucl Cardiol. 2019; 26: 2065-2123
- (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy.J Am Coll Cardiol. 2016; 68: 1323-1341
- How to image cardiac amyloidosis: a practical approach.JACC Cardiovascular imaging. 2020; 13: 1368-1383
- Right ventricular dilation in primary amyloidosis: an independent predictor of survival.Am J Cardiol. 1997; 80: 486-492
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging.Journal of Nuclear Cardiology. 2019; 26: 2065-2123
- Light chain amyloidosis: the heart of the problem.Haematologica. 2013; 98: 1492-1495
- Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.J Am Coll Cardiol. 2016; 68: 1014-1020
- Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey.JACC CardioOncol. 2021; 3: 537-546
- Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution.JACC Cardiovascular imaging. 2021; 14: 1221-1231
- How to image cardiac amyloidosis.Circulation Cardiovascular imaging. 2014; 7: 552-562
- Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.Clin Chem. 2009; 55: 499-504
- Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.Heart. 2012; 98: 1442-1448
- Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis.JACC Cardiovascular Imaging. 2020; 13: 909-920
- Independent prognostic value of stroke volume index in patients with immunoglobulin light chain amyloidosis.Circulation Cardiovascular imaging. 2018; 11: e006588
- Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system.JACC Cardiovascular imaging. 2017; 10: 398-407
- Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.Eur Heart J. 2022; 43: 333-341
- Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med. 2018; 379: 1007-1016
Aimo A, Merlo M, Porcari A, et al. 2022. P292 REDEFINING THE EPIDEMIOLOGY OF CARDIAC AMYLOIDOSIS. A SYSTEMATIC REVIEW OF SCREENING STUDIES. Eur Heart J, 24(Supplement_C), pp.suac012-281.
- Binding of serum amyloid P-component (SAP) by amyloid fibrils.Clin Exp Immunol. 1979; 38: 284-293
- Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.Eur J Nucl Med Mol Imaging. 2018; 45: 1945-1955
- State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.J Nucl Cardiol. 2019; 26: 158-173
- Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis.Cardiovasc Pathol. 2016; 25: 413-417
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases.Eur Heart J. 2021; 42: 1554-1568
- Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation. 2016; 133: 2404-2412
- Follow-up technetium-99m stannous pyrophosphate myocardial scintigrams after acute myocardial infarction.Circulation. 1977; 56: 181-187
- Hydroxychloroquine-Mediated Cardiotoxicity with a False Positive 99M-Technetium Labeled Pyrophosphate Scan for Amyloidosis.J Card Fail. 2017; 23: S46-S47
- Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.European Heart Journal Cardiovascular Imaging. 2017; 18: 1344-1350
- Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.Eur J Heart Fail. 2021; 23: 895-905
- Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression.JACC Cardiovascular imaging. 2021; 14: 189-199
- Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT.J Nucl Med. 2021; 62: 716-722
- Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.JACC Cardiovascular Imaging. 2020; 13: 1314-1321
- Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.J Am Coll Cardiol. 2005; 46: 1076-1084
- Use of florbetapir-PET for imaging beta-amyloid pathology.JAMA. 2011; 305: 275-283
- Positron emission tomography for cardiac amyloidosis: timing matters.J Nucl Cardiol. 2022; 29: 790-797
- Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis.J Nucl Cardiol. 2020; 27: 123-132
Article info
Publication history
Published online: February 23, 2023
Identification
Copyright
© 2023 Elsevier Inc. All rights reserved.
